Cancer metabolism gets physical

The physical microenvironment regulates cancer cell metabolism, and engineered culture systems need to reflect physical properties of tumors. Patient-derived culture models enable assessment of drug sensitivity and can connect personalized genomics with therapeutic options. However, their clinical translation is constrained by limited fidelity. We outline how the physical microenvironment regulates cell metabolism and describe how engineered culture systems could enhance the predictive power for precision medicine.

[1]  Brendon M. Baker,et al.  Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues , 2012 .

[2]  Michael W Davidson,et al.  Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate. , 2014, Cancer research.

[3]  M. Turunen,et al.  Myc requires RhoA/SRF to reprogram glutamine metabolism , 2018, Small GTPases.

[4]  Matija Snuderl,et al.  Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. , 2013, Cancer research.

[5]  Stephanie I. Fraley,et al.  A distinctive role for focal adhesion proteins in three-dimensional cell motility , 2010, Nature Cell Biology.

[6]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[7]  D. Pette,et al.  Binding of glycolytic enzymes to structure proteins of the muscle. , 1968, European journal of biochemistry.

[8]  Hans Clevers,et al.  Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts , 2017, Nature Reviews Cancer.

[9]  Zhi Wei,et al.  Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. , 2018, Cancer discovery.

[10]  Christopher S. Chen.  Mechanotransduction – a field pulling together? , 2008, Journal of Cell Science.

[11]  Violena Pietrobon.  Cancer metabolism , 2021, Cell.

[12]  L. Munn,et al.  Aberrant vascular architecture in tumors and its importance in drug-based therapies. , 2003, Drug discovery today.

[13]  D. Hardie.  AMPK--sensing energy while talking to other signaling pathways. , 2014, Cell metabolism.

[14]  Brendon M. Baker,et al.  Rapid casting of patterned vascular networks for perfusable engineered 3D tissues , 2012, Nature materials.

[15]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[16]  Cynthia A. Reinhart-King,et al.  Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.

[17]  William McLamb,et al.  Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs , 2016, Scientific Reports.

[18]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[19]  Hidetoshi Kotera,et al.  Integrating perfusable vascular networks with a three-dimensional tissue in a microfluidic device. , 2017, Integrative biology : quantitative biosciences from nano to macro.

[20]  Stephanie J Hachey,et al.  3D microtumors in vitro supported by perfused vascular networks , 2016, Scientific Reports.

[21]  Donald E Ingber,et al.  Reverse Engineering Human Pathophysiology with Organs-on-Chips , 2016, Cell.

[22]  F. Ginhoux,et al.  Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma , 2016, Oncoimmunology.

[23]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[24]  Claudia Fischbach,et al.  3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways. , 2015, Biomaterials.

[25]  David A. Rand,et al.  Systems Chronotherapeutics , 2017, Pharmacological Reviews.

[26]  O. Feron,et al.  Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[28]  Vernella Vickerman,et al.  Design, fabrication and implementation of a novel multi-parameter control microfluidic platform for three-dimensional cell culture and real-time imaging. , 2008, Lab on a chip.

[29]  M. Yarmush,et al.  A microfluidic hepatic coculture platform for cell-based drug metabolism studies. , 2010, Biochemical pharmacology.

[30]  Hao Wu,et al.  Beyond Warburg effect – dual metabolic nature of cancer cells , 2014, Scientific Reports.

[31]  L. Cantley,et al.  Obesity and Cancer Mechanisms: Cancer Metabolism. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[33]  C. Dang,et al.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.

[34]  M. Simon,et al.  Oxygen availability and metabolic adaptations , 2016, Nature Reviews Cancer.

[35]  Mandy B. Esch,et al.  The role of body-on-a-chip devices in drug and toxicity studies. , 2011, Annual review of biomedical engineering.

[36]  D. Schlaepfer,et al.  Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.

[37]  J. Bass,et al.  Circadian topology of metabolism , 2012, Nature.

[38]  David E. Fisher,et al.  Precision medicine for cancer with next-generation functional diagnostics , 2015, Nature Reviews Cancer.

[39]  Abhishek K. Jha,et al.  Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. , 2016, Cell metabolism.

[40]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[41]  Jong Hwan Sung,et al.  A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. , 2010, Lab on a chip.

[42]  J. Erler,et al.  Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK , 2013, Oncogene.

[43]  D. Anastasiou.  Tumour microenvironment factors shaping the cancer metabolism landscape , 2016, British Journal of Cancer.

[44]  D. Fruman,et al.  Cancer: A targeted treatment with off-target risks , 2017, Nature.

[45]  G. Christofori,et al.  Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy , 2015, Cell reports.

[46]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[47]  Mina J Bissell,et al.  Tumor reversion: Correction of malignant behavior by microenvironmental cues , 2003, International journal of cancer.

[48]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[49]  J. Loscalzo,et al.  Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. , 2016, The Journal of clinical investigation.

[50]  G. Hotamisligil,et al.  Foundations of Immunometabolism and Implications for Metabolic Health and Disease. , 2017, Immunity.

[51]  Xin Gao,et al.  Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase , 2017, Cell.

[52]  Ying Zheng,et al.  Formation of microvascular networks in vitro , 2013, Nature Protocols.

[53]  P. Iversen,et al.  Interstitial fluid: the overlooked component of the tumor microenvironment? , 2010, Fibrogenesis & tissue repair.

[54]  O. Sampetrean,et al.  Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model. , 2014, Neuro-oncology.